SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

2/6/24 10:38:54 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ASLN alert in real time by email

SC 13G 1 13G_ASLN.txt 13G- INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) ASLAN Pharmaceuticals Limited. (Name of Issuer) ----------------------------------------------------------- Ordinary Shares as represented by American Depository Shares (ADSs),par value $0.01 per ordinary share (Title of Class of Securities) ----------------------------------------------------------- 04522R200 (CUSIP Number) ----------------------------------------------------------- Dec 29, 2023 (Date of Event Which Requires Filing of this Statement) ----------------------------------------------------------- Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d 1(b) / / Rule 13d 1(c) / / Rule 13d 1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act)or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.04522R200 1. Names of reporting persons UBS Group AG directly and on behalf of certain subsidiaries. ----------------------------------------------------------- 2. Check the appropriate box if a member of a group a / / b / / See Item 8 of attached schedule ----------------------------------------------------------- 3. SEC use only ----------------------------------------------------------- 4. Citizenship or place of organization Switzerland ----------------------------------------------------------- Number of shares beneficially owned by each reporting person with: Number of 5. Sole Voting Power Shares Bene- 6. Shared Voting Power 16,917,600 ficially 7. Sole Dispositive Power Owned by Each 8. Shared Dispositive Power 16,917,600 ----------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 16,917,600 ----------------------------------------------------------- 10. Check if the aggregate amount in Row (9) excludes certain shares (see instructions) Shares / / ----------------------------------------------------------- 11. Percent of class represented by amount in Row (9) 8.91% ----------------------------------------------------------- 12. Type of reporting person (see instructions) BK ----------------------------------------------------------- Item 1(a) Name of issuer: ASLAN Pharmaceuticals Limited ----------------------------------------------------------- Item 1(b) Address of issuer's principal executive offices: 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 ----------------------------------------------------------- 2(a) Name of person filing: UBS Group AG ----------------------------------------------------------- 2(b) Address or principal business office or, if none, residence: UBS Group AG Bahnhofstrasse 45 PO Box CH-8021 Zurich, Switzerland ----------------------------------------------------------- 2(c) Citizenship: Switzerland ----------------------------------------------------------- 2(d) Title of class of securities: Ordinary Shares as represented by American Depository Shares (ADSs), par value $0.01 per ordinary share ----------------------------------------------------------- 2(e) CUSIP No.: 04522R200 ----------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d 1(b) or 240.13d 2(b) or (c), check whether the person filing is a: (a) / / Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) /X /Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) / / Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) / / Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a 8); (e / / An investment adviser in accordance with Section 240.13d 1(b)(1)(ii)(E); (f) / / An employee benefit plan or endowment fund in accordance with Section 240.13d 1(b)(1)(ii)(F); (g) // A parent holding company or control person in accordance with Section 240.13d 1(b)(1)(ii)(G); (h) / / A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) / / A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a 3); (j) / / A non-U.S. institution in accordance with Section 240.13d 1(b)(1)(ii)(J); (k) / / Group, in accordance with Section 240.13d 1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d 1(b)(1)(ii)(J), please specify the type of institution: ________________________________ ----------------------------------------------------------- Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 (a) Amount beneficially owned:16,917,600 (b) Percent of class: 8.91% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote _________ (ii) Shared power to vote or to direct the vote 16,917,600 (iii) Sole power to dispose or to direct the disposition of _________ (iv) Shared power to dispose or to direct the disposition of 16,917,600 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following / /. Dissolution of a group requires a response to this item. Item 6. Ownership of More than 5 Percent on Behalf of Another Person. N/A ----------------------------------------------------------- Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. This statement on Schedule 13G is being filed by UBS Group AG on behalf of itself and its wholly owned subsidiary UBS Financial Services Inc. .On 12 June 2023, UBS Group AG acquired Credit Suisse Group AG, succeedingby operation of Swiss law to all assets and liabilities of Credit Suisse Group AG and became the direct orindirect shareholder of all of the former Credit Suisse Group AG's direct and indirect subsidiaries (theTransaction). ----------------------------------------------------------- Item 8. Identification and Classification of Members of the Group. N/A ----------------------------------------------------------- Item 9. Notice of Dissolution of Group. N/A ----------------------------------------------------------- Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under Section 240.Sub Section14a-11. Signatures After reasonable inquiry and to the best of my knowledge and belief,I certify that the information set forth in this statement is true, complete and correct. Date: 02/06/2024 Signature: /s/ Name: Andrew Johnson Title: Director Date: 02/06/2024 Signature: /s/ Name:Rollins Simmons Title: Authorized Signatory

Get the next $ASLN alert in real time by email

SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

Chat with this insight

Recent Analyst Ratings for
$ASLN

$ASLN
Financials

Live finance-specific insights

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

$ASLN
Leadership Updates

Live Leadership Updates

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer

ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration

$ASLN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on ASLAN Pharmaceuticals with a new price target

HC Wainwright & Co. reiterated coverage on ASLAN Pharmaceuticals with a new price target

$ASLN
Large Ownership Changes

This live feed shows all institutional transactions in real time.